Metformin may increase risk of cognitive impairment

September 21, 2013
Metformin may increase risk of cognitive impairment
Metformin may increase the risk of cognitive impairment in patients with diabetes; however, calcium supplementation may attenuate this risk, according to research published online Sept. 5 in Diabetes Care.

(HealthDay)—Metformin may increase the risk of cognitive impairment in patients with diabetes; however, calcium supplementation may attenuate this risk, according to research published online Sept. 5 in Diabetes Care.

Eileen M. Moore, Ph.D., of the University of Melbourne in Australia, and colleagues conducted a subgroup analysis involving 104 patients with type 2 diabetes and 22 patients with impaired who participated in the Australian Imaging, Biomarkers and Lifestyle study of aging. The authors sought to determine whether metformin, serum vitamin B12, or calcium supplements are associated with cognitive impairment in patients with diabetes.

The researchers found that, overall, patients with diabetes were 51 percent more likely to exhibit cognitive impairment than those without diabetes, and those taking metformin were more than twice as likely (2.23-fold) to exhibit cognitive impairment. After adjusting for age, sex, level of education, history of depression, serum vitamin B12, and metformin use, cognitive performance was improved for those patients who were also taking .

"Adequately powered, prospective, controlled trials are warranted to investigate further the association between diabetes, , and the effect of metformin therapy, as well as the possible amelioration using vitamin B12 and/or ," the authors write.

Several authors disclosed financial ties the biotechnology industry.

Explore further: Considerably more patients may benefit from effective antidiabetic drug

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Imeglimin beneficial as add-on to metformin in T2DM

December 14, 2012

(HealthDay)—For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, according to ...

Post-breast cancer, metformin has no effect on mortality

July 3, 2013

(HealthDay)—For older women with diabetes and breast cancer, there is no association between metformin use and all-cause or breast cancer-specific mortality, according to a study published online April 30 in Diabetes Care.

Recommended for you

Diets avoiding dry-cooked foods can protect against diabetes

August 24, 2016

Simple changes in how we cook could go a long way towards preventing diabetes, say researchers at the Icahn School of Medicine at Mount Sinai. A new randomized controlled trial, published online July 29 in the journal Diabetologia, ...

New study reveals a novel protein linked to type 2 diabetes

August 16, 2016

Findings from Boston University School of Medicine (BUSM), which appear in eLife, provide a possible explanation as to why most people who are obese develop insulin resistance and type 2 diabetes. A minority of obese individuals, ...

Gene variant explains differences in diabetes drug response

August 9, 2016

The first results from a large international study of patients taking metformin, the world's most commonly used type 2 diabetes drug, reveal genetic differences among patients that may explain why some respond much better ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.